



iJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 Issue: IV Month of publication: April 2025

DOI: <https://doi.org/10.22214/ijraset.2025.69030>

www.ijraset.com

Call:  08813907089

E-mail ID: ijraset@gmail.com

Review on Pharmacovigilance

Priyanka Kotwal¹, Ketakee More², Arti Gadade³, Nitin Gawai⁴, Priyanka Godase⁵

B Pharmacy Department, Mahadev Kanchan College Of Pharmaceutical Education And Research Uruli Kanchan , Pune ,
Maharashtra, India.

Abstract: *In order to treat their illnesses and enhance their health, patients take medication. In addition to its therapeutic benefits, medicine can sometimes be harmful. Pharmacovigilance studies were conducted to control and monitor drug risk at every stage of a product's lifetime, from development to post-marketing for general public usage. In order to improve knowledge advancement through scientific theories, concepts, and ideas, this review was conducted to evaluate pharmacy students. Patients take medication to improve their health and treat their ailments. Medicine has therapeutic benefits, but it can also be dangerous at times. To regulate and monitor drug risk at every stage of a product's lifecycle, from development to post-marketing for general public use, pharmacovigilance studies were carried out. This evaluation was carried out to assess pharmacy students in order to enhance knowledge improvement through scientific theories, concepts, and ideas. This study was confirmed, modified, and adapted from previous studies.*

Keywords: *ICH E2e Guidelines, Clinical Research, Regulatory Bodies, Good Clinical Practice, and Pharmacovigilance Concept.*

I. INTRODUCTION

Pharmacovigilance is the study of drug safety. Pharmacovigilance, according to the World Health Organization (WHO), is the study and practice of identifying, assessing, understanding, and preventing adverse effects or any other problem with drugs or vaccines.[1] Pharmacovigilance must be used in every nation as a means of addressing medication problems and reducing or eliminating adverse drug reactions.

A common approach for reporting and discovering negative effects of drugs is the reporting system.

Improving important reporting should need automated reporting. Active detailing, knowledge discovery in data, and chart critique should all be used to enhance automated reporting.

An improved automated technique for observing the extremely detailed ADR signals was created recently. When new medications are introduced, rare adverse drug reactions occur. Due to the rapid release of this medication, there is a lack of information on the recently discovered chemicals, which increases the possibility of unfavorable drug responses.

a pharmacovigilance research after observing a link between the use of thalidomide during pregnancy and severe, deadly abnormalities.

Despite being a member of the Uppsala Monitoring Center Program, India contributes very little to the database. Among the many functions that PV completes are the identification, measurement, and documentation of drug-related problems that result in drug malformations. PV occurs during the post-marketing stage of drug development.

II. CLINICAL RESEARCH

The goal of clinical trials, also known as clinical studies, is to help identify the most effective and safe method of delivering a new medication to people. A clinical trial is an organized research study that looks at new methods of preventing, detecting, diagnosing, or treating illness or disease in an effort to improve a patient's quality of life.

It is a methodical investigation of novel medications in people to produce information for detecting and/or verifying the pharmacological, clinical, and/or adverse effects in order to ascertain the efficacy and/or safety of new drugs, according to the amended Schedule Drugs and Cosmetics Act of 2005.

Stages of Clinical Research

The types of trials that are conducted on humans generally fall into four stages. For example, early human dosage finding and toxicity data, indications of potential activity, comparisons with a standard to assess efficacy, and post-marketing trials are all necessary for the development of a new medication.

There may or may not be precise similarities in other uses, as the Phase I, II, III, and IV nomenclature was created for drug development objectives.

A. PHASE 0 CLINICAL TRIALS

Since the Phase I, II, III, and IV nomenclature was developed for drug research purposes, there might or might not be exact parallels in other applications.

Phase 0 clinical trials

In order to address the growing challenge of delivering breakthrough findings in fundamental science to the market where patients may use them, the National Institutes of Health (NIH) laid out certain initiatives in September 2003.

The NIH budget and US pharmaceutical R&D expenditures increased dramatically between 1993 and 2003, while the FDA received fewer substantial submissions of pharmacological and biological products. Between 1995 and 2000, the amount of money required for a single successful drug launch was \$1.1 billion; between 2000 and 2002, that number increased to \$1.7 billion. The critical road began with the selection of potential products for development and was challenging, costly, and ineffective. Clinical failures included safety concerns and ineffectiveness. Alarm was raised by the widening gap between clinical application and knowledge, as well as by stagnation and declining innovation. One that began Phase I trials in 1985 had no more chance of getting on sale than one that began in 2000.

B. PHASE I

Tolerability, pharmacokinetics, and pharmacodynamics are evaluated. Clinical researchers usually manage trials with 20–100 participants. The dosage is raised when patients are evaluated to determine whether they are responding to the treatment and no significant side effects are observed. The best and safest dose that can be administered is determined by these escalation dose studies, which are a fraction of the dose that proved hazardous during animal research.

Rule based designs enable dosage escalation and de-escalation with decreasing fractions of the prior dose based on the presence of certain conditions and do not require any prior assumptions on the dose-toxicity curve or absence of toxicity.

The initial dosage is estimated by extrapolating data from animal toxicology. If a dose-limiting hazard occurs in one patient, the same dose is given to three more. Dose escalation is carried out in a group of three to six individuals until at least two of them experience toxicities that limit their dosage.

C. PHASE II

The intervention's potential for therapeutic effect is not presumed. While giving therapeutic doses determined during Phase I, the clinical researcher keeps an eye on the patients. Trials often take place in a multi-institution context.

When the drug begins to have adverse effects or not function as intended the development process is usually completed at this Phase II.

Phase II research design is based on the quality and adequacy of Phase I research. In both stages, the type of patient enrolled is a vulnerability. Designs including case series and randomized clinical trials have been used. Both single-stage and multi-stage Phase II clinical trials are often designed with a single goal in mind.

Other designs have multiple stages or a sequential element. The author recommends the method that best meets the needs of the study.

D. PHASE III

These types of scientific clinical study on new treatments are the most rigorous and comprehensive.

The trials may be difficult to organize and carry out. Trial types include factorial designs, uncontrolled trials (single therapy), historical controls, no-randomized concurrent trials, and randomized controlled studies, and large groups (100–3000 humans) are recruited.

The patients are monitored by both the clinical researcher and their personal physician. There are two types of phase III clinical trials: Phase IIIA trials, which are carried out after the effectiveness of the therapy has been determined but before a New Drug Application (NDA) or other dossier is submitted to the regulatory body, and Phase IIIB trials, which are carried out after an NDA or other dossier has been submitted but before approval and launch. An established surrogate for one of these, life extension, or improved health-related quality of life should be utilized to demonstrate efficacy, according to guidance letters given by the FDA in the 1980s. If the new treatment results in a statistically significant improvement, it is usually approved for clinical use.

E. PHASE IV

After being approved by the FDA, therapies that have been proven to be high-quality, safe, and effective may be made accessible to the general public. Both patients and their physicians anticipate benefits. However, not all issues with efficacy or safety have been noted. The FDA requires continuous assessment after release to evaluate safety signs that may affect the benefit-risk ratio.

Their own physician monitors treatment results. The effectiveness and detection of rare or long-term side effects over a much bigger patient population and longer time period are evaluated, pharmacogenetics is investigated, and healthcare costs and outcomes are determined. The FDA may require a developer to conduct a Phase IV trial before approving a medication. Less than half of the studies are completed or even initiated by developer. A drug may be taken off the market or limited to certain applications as a result of phase IV trials.

These studies functioned similarly to Phase III research and were first conducted for marketing goals. The research was carried out at institutions with investigators with clinical trial experience, and its inclusion and exclusion criteria were similar to those of Phase III studies. The results were not consistent with what would be expected under normal conditions. As a result, novel studies were developed to involve ordinary physicians in unaware research communities. There are now additional goals, such as assessing specific pharmacological effects, determining the frequency of adverse reactions, determining the impact of long-term therapy administration, creating a new clinical indication for the therapy, assessing the therapy in groups in higher risk, etc.

III. DRUG CONTROLLER GENERAL OF INDIA (DCGI)

The DCGI creates regulations concerning the manufacture, distribution, importation, and sale of pharmaceuticals in India.

The Central Drugs Standard Control Organization (CDSCO), an Indian drug regulatory body under DCGI's leadership, is tasked with authorizing new drugs, monitoring clinical trials, and ensuring the quality of pharmaceuticals and cosmetics distributed throughout the nation.

Responsibilities of DCGI

- Acting as the last adjudicator in any dispute about the quality of pharmaceuticals.
- Setting and maintaining a national standard. • To provide uniformity in the application of the Drugs and Cosmetics Act.
- Drug analysts are educated by State Drug Control Laboratories and other organizations.

The zonal offices are located in Hyderabad, Ghaziabad, Hyderabad, Chennai, Kolkata, and Mumbai. standard for inspection and enforcement.

Sub-zonal offices in Chandigarh, Jammu, and Bangalore These centers communicate with the state drug control authorities that fall within their purview in order to guarantee consistent standards of inspection and enforcement.

IV. CENTRAL DRUG STANDARD CONTROL ORGANIZATION (CDSCO)

The job of CDSCO is to approve new medications material that meets the criteria for a new medicine under the medicine and Cosmetic Act and is only approved by CDSCO.

- 1) *Clinical trial approval:* In India, only CDSCO has the authority to approve clinical trials in accordance with the Drug and Cosmetic Act. All information pertaining to experimental medications must be included in the application that the applicant submits. License and registration for the importation of medications. In 1945, changes were made to the 1940 Drug and Cosmetic Act and associated rules. Drugs and cosmetics are prohibited Drug export license and registration.
- 2) *The central government's role:* The state drug controller is in charge of licensing facilities that manufacture and sell medications and cosmetics.
Concurrent lists, state lists, and union lists.

V. TYPES OF REGULATORY APPLICATIONS

A. Investigational Of New Drug

Types:

- The Investigator IND application
- Use the IND app in an emergency.
- IND application for therapeutic drug.

1) *Table of Contents and Cover Sheet:*

- Selecting the clinical research stage that will be conducted.
- A commitment to wait for FDA approval of the IND application before conducting clinical research.
- A commitment that an Institutional Review Board (IRB) would examine and approve each proposed clinical investigation and that the investigator will inform the IRB of any suggested changes to the study.
- A person's name and title who reviews and evaluates the drug safety info.

2) *General Investigational Plan and Introductory Statement*

The name, active ingredient, pharmacological class, structural formula, dosage form formulation, mean of administration, targets, and predicted duration of the proposed drugs are all part of a brief introduction. A recap of ahead of human experiences with the drug therapy, referring other INDs and, if pertinent examine or marketing experiences in other nations regarding the safety of the proposed clinical investigations; The nation and the reasons for the drug's withdrawal should be provided if the medication has been taken off the market or from investigation in any nation for safety or efficacy-related reasons.

Protocols:

Every proposed trial or study that wasn't originally submitted in the IND should have a protocol. Details on the clinically necessary study components, like blood chemistries and vital sign monitoring, should also be included in phase I protocols.

Information on Chemistry, Manufacturing, and Control (CMC)

3) *Pharmacology and Toxicology Information*

- The sponsor should submit information about the drug's pharmacological and toxicological studies that support their conclusion that the intended clinical investigations may be carried out safely.
- Pharmacy and the Disposition of Drugs
- Prior Human Exposure to the Experimental Drug
- If the drug under research has previously been studied or sold in Saudi Arabia or elsewhere, specific details regarding the experience that are suitable for the proposed investigation's safety should be included.
- A list of all the countries where the drug has been marketed and where it has been taken off the market, if the drug has been studied or sold outside of Saudi Arabia.

B. *New Drug Application (NDA)*

The NDA's general format

The complete application's detailed table of contents is called the index. In the event that the reviewer contacts the drug regulatory staff, the sponsor should maintain extra copies of the index and provide them.

The fiche number should be mentioned if microfiche has been used for any portions of an application. A copy of the index and a customized table of contents based on pertinent sections of the application index should be maintained by each technical review department.

Archival Copy

It serves as a reference source for the FDA reviewer and other FDA officials to find information that is not included in the review copy section that is assigned to them. Copies of tabulations and clinical trial case report forms are also obtained from it.

Examine the copy

The application's review copy is separated into five or six components, such as statistics and pharmacology. include the scientific and technical data that the FDA reviewers requested.

A copy of the application form, the FDA cover letter, an index to all applications, an overall summary, and a reference or authorization letter to access NDAs, DMFs, and other documents are all required.

C. *Abbreviated New Drug Applications*

Abbreviated New Drug Applications: The FDA's Office of Generic Drugs, Center for Drug Evaluation and Research, receives the ANDA and reviews it before approving a generic medication.

After being accepted, the applicant can produce and sell the generic medication to give the general public a low-cost, safe, and efficient substitute.

A list of all approved medications, that include innovator and generic, can be located in the FDA's Approved drugs with Therapeutic Equivalence Evaluations (Orange Book).

Generic drugs.

ANDA's objective

- To keep medication a cheaper option.
- To shorten the drug's development period; • To boost the drug's bioavailability relative to reference list drugs.

VI. GOOD CLINICAL PRACTICE

It is primarily recognised as the regulating ethical code since it forbids doing harm to patients. nevertheless considering the complexity in contemporary medical research, a more extensive set of principles that address physician's ethical as well as scientific obligations including getting informed permission or stating risks when doing biomedical research. A set of rules for biomedical research that covers the planning, execution, conclusion, audit, analysis, reporting, and documenting of studies involving human participants is known as "good clinical practice. It seeks to guarantee that the clinical characteristics of the pharmaceutical drugs being studied are accurately documented and that the investigations are ethically and scientifically sound. The recommendations aim to establish two fundamental principles: safeguarding human subjects' rights and ensuring the validity of biomedical data produced.

These rules were developed taking into account the Ethical rules for Biomedical Research on Human Subjects published by the Indian Council of Medical Research, as well as WHO, ICH, USFDA, and European GCP guidelines. They ought to be adhered to when doing biomedical research in India at any point during the drug development process, whether before or after the product is registered in India.

DEFINITIONS The Act refers to the Drugs & Cosmetics Act 1940 (23 of 1940) and it implementing regulations, when applicable.

An adverse event (AE) is any undesirable medical event that occurs in a patient or human volunteer while receiving pharmacological treatment; these events may include symptoms, diseases, or abnormal laboratory results, and they are not always related to the medicine being administered. See Serious Adverse Event as well.

VII. DRUG ADVERSE REACTION (ADR)

Regarding pharmaceutical goods that have been approved: An unpleasant and unexpected reaction at dosages typically used or examined in humans. In the event that pharmaceuticals are newly unregistered or have not yet received approval for the medical condition for which they are being tested: An unpleasant and unexpected reaction at any dosage(s) ADR is not the same as AE; in the former scenario, there seems to be a plausible link between the adverse event and the medication under investigation. An adverse drug reaction (ADR) in clinical trials is also defined as a medical event that appears to be brought on by overdose, addiction or dependence, or combinations with other medications. There are two types of adverse medication reactions: pharmacological (type A) and idiosyncratic (type B). Because they are dose-dependent, they can be easily reversed by lowering the dosage or stopping the medication. On the other hand, type B adverse responses are strange and unpredictable based on the drug's recognized pharmacology.

Audit of a Trial

A methodical check of the study conducted by those not directly involved, including:

(a) Analyze relevant actions to ascertain compliance with the Protocol; (b) Examine data to make sure Source Documents are free of inconsistencies. The examination

should also contrast the intermediate or final report's data with that found in the Source Documents. It should also seek to determine whether methods that could compromise the veracity of the data were used in their creation.

(c) Adherence to the Standard Operating Procedures (SOPs) that were adopted

Masking and Blinding

a kind of "control experimentation" when the therapy being administered is kept a secret from one or more participants. Double blind means that the study subject(s), investigator(s), monitor, and data analyst(s) are not aware of the therapy that has been assigned, whereas single blind means that the study subject(s) are not aware.

The case record form's structure and layout should enable precise data entry, display, validation, audit, and examination.

Clinical Study or Clinical Trial

clinical, pharmacological (including pharmacodynamics and pharmacokinetics), and/or adverse effects of pharmaceutical products on human subjects (whether patients or non-patient volunteers) in order to identify or confirm their safety and effectiveness.

VIII. CONCEPT OF PHARMACOVIGILANCE

Effective information management is inextricably tied to pharmacovigilance, which is the science and practice of identifying, evaluating, comprehending, and preventing side effects or other drug-related issues. Pharmacovigilance, a method of collecting, evaluating, and sharing data for optimal patient safety, relies heavily on information.

A strong information system that makes it easier to gather adverse event reports from patients, healthcare providers, and other stakeholders is the cornerstone of pharmacovigilance. The development of data sources, with a focus on integrating wearable technology, electronic health records, and empirical evidence to increase the scope and depth of data available for analysis. How to leverage those tools to enhance regulatory decision-making, identify safety concerns, and sift through big information.

Effective risk management strategies can be developed and a proactive reaction to new risks is ensured by timely and transparent sharing of safety information.

The ongoing assessment of information management techniques in order to adjust to the complexity of contemporary pharmaceutical innovation and healthcare. Essentially, this abstract highlights the mutually beneficial relationship between information management and pharmacovigilance, demonstrating how the efficient use of varied, high-quality data is essential to improving drug safety procedures and protecting the public's health.

IX. INTERNATIONAL CONFERENCE ON HARMONIZATION (ICH) E2E GUIDELINES PHARMACOVIGILANCE PLAN

Guidelines for a Pharmacovigilance Plan's structure are provided in this section. The Safety Specification ought to serve as the foundation for the Pharmacovigilance Plan. It is possible to write the Specification and Plan as two separate documents. The sponsor would typically create the plan, which might be reviewed with regulators during product development, before a new product is approved (i.e., when the marketing application is submitted), or once a safety issue emerges after the product has been marketed.

REFERENCES

- [1] Beninger P. Signal management in pharmacovigilance: a review of activities and case studies. Clin Ther. 2020;42(6):1110-29. doi: 10.1016/j.clinthera.2020.04.003. Available from: <https://pubmed.ncbi.nlm.nih.gov/32487428/>
- [2] Abubakar AR, Simbak NB, Haque M. Pharmacovigilance study: awareness among medical students of new medical college of Malaysia. Int J Pharm Pharm Sci. 2023;7(1):83-8. Available from: <https://journals.innovareacademics.in/index.php/ijcpr/article/view/5344>
- [3] Nimesh S, Aswalayan VD. Pharmacovigilance: an overview. Int J Pharmacol. 2013;3(1):1-6. Available from: <https://www.ijcap.in/html-article/22037>
- [4] Garg T, Singh O, Arora S. Opportunities and growth of conducting clinical trials in India. Int J Pharm Sci Rev Res. 2013;8(1):152-60. Available from: https://www.researchgate.net/publication/276499011_Clinical_Trial_Phases
- [5] Mahan VL. Clinical trial phases. Int J Clin Med. 2014;5(21):1374-83. doi: 10.4236/ijcm.2014.521175. Available from: <https://www.scirp.org/journal/PaperInfoForCitation?PaperID=52733>
- [6] Dhole SD, Darade RB. Indian pharmaceutical regulatory authority: review. Int J Pharm Sci. 2013;2:1109-19. Available from: https://www.researchgate.net/publication/276499011_Clinical_Trial_Phases
- [7] Ramteke A, Bilai M, Sufi, Deolekar RL, Pathik C. A review on CDSCO: Central Drugs Standard Control Organisation. Int J Adv Res Sci Commun Technol. 2018;3(1):569-71. Available from: https://www.researchgate.net/publication/276499011_Clinical_Trial_Phases
- [8] Rajiv Gandhi Centre for Biotechnology. Good clinical practice guidelines (India). Thiruvananthapuram: Rajiv Gandhi Centre for Biotechnology; 2018. Available from: https://www.researchgate.net/publication/276499011_Clinical_Trial_Phases
- [9] Ilango KB, Kumar V, Lakade SH. Textbook of industrial pharmacy II. 2nd ed. Mumbai: Nirali Prakashan; 2018. Available from: https://www.researchgate.net/publication/276499011_Clinical_Trial_Phases
- [10] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guidelines pharmacovigilance planning E2e. Geneva: International Conference on Harmonisation; 2001. Available from: https://www.researchgate.net/publication/276499011_Clinical_Trial_Phases
- [11] Bharati A, Dubey T, Thakur R, Bhosale K, Bhoir P. A review article of pharmacovigilance and studies of clinical research for health care. IP Int J Compr Adv Pharmacol. 2024;9(2):116-24. doi: 10.18231/j.ijcaap.2024.017. Available from: <https://www.ijcap.in/article-details/22037>



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)